Twentyeight-Seven Therapeutics has officially launched with $65m in series A funding to commercialise oncology treatments based on research at Harvard Medical School.
Twentyeight-Seven Therapeutics (28-7), a US-based cancer-focused biotechnology spinout of Harvard University, launched on Thursday with $65m in series A funding co-led by Novartis Venture Fund, the investment arm of pharmaceutical firm Novartis.
Investment firm MPM Capital co-led the round, which also featured Johnson & Johnson Innovation – JJDC and Astellas Venture Management, the respective corporate venture capital units of healthcare group Johnson & Johnson and pharmaceutical firm Astellas Pharma.
Vertex Ventures HC, a venture capital fund of Singaporean state-owned VC…
